Bayer Animal Health by b2oGBV


									Bayer Animal Health:

Bayer to expand Companion Animal Portfolio with two new EU
product approvals

First launches in Germany and Austria to follow shortly

Monheim, April 26, 2011 – Bayer today announced that the European Commission has
approved two new companion animal products: Veraflox® (pradofloxacin) and Procox®
(emodepside and toltrazuril). Veraflox® is the first next-generation veterinary
fluoroquinolone antibiotic for the treatment of bacterial infection in cats and dogs. Procox®
is the first and only licensed combination treatment for roundworm and coccidia in dogs.

“Bayer Animal Health is proud to introduce these two innovative treatments which will
provide veterinarians with much needed, effective new treatment options for a range of
indications,” said Jean-Luc Lowinski, Managing Director of Bayer Animal Health. “As an
expert solution provider for animal health we have a strong and ongoing commitment to
researching and developing innovative ways to address parasitic and bacterial infections
in companion animals.”

Veterinary antibiotics such as fluoroquinolones are an essential weapon in the fight
against infections in companion animals worldwide. There have, however, been no major
advances in the class since the introduction of the first veterinary fluoroquinolone by
Bayer Animal Health over 20 years ago.

Veraflox® is the first next-generation veterinary fluoroquinolone antibiotic for the treatment
of bacterial infection in cats and dogs and marks the first major advance in the
fluoroquinolone market in many years. Veraflox®’s mode of action gives it enhanced
antibacterial activity compared with existing fluoroquinolones, including extended
spectrum efficacy against Gram-positive and anaerobic pathogens. The European

                                          - 1/3 -
Commission granted approval for the treatment of the following infections caused by
specified and susceptible pathogens: wound infections, superficial and deep pyoderma
(bacterial skin infections), acute urinary tract infections, and, as adjunctive treatment for
severe gingival (gum) and periodontal tissue infections in dogs, and against wound
infections, abscesses and acute upper respiratory tract infections in cats (oral
suspension). Veraflox is approved in 30 European countries and will be launched in the
first markets shortly.

Procox® is the first parasiticide of its kind for the combination treatment of roundworm and
coccidia gastrointestinal parasitic infections in dogs, including puppies of at least two
weeks of age and weighing at least 0,4 kg. This is important as puppies are extremely
susceptible to parasitic infections in their early months. Roundworms are often transmitted
from the mother to the newborn, and coccidia frequently occur during the first month of
life. Due to its single dose suspension formulation, which can be taken from two weeks of
age, Procox® offers an easy and convenient first time treatment option for puppies.
Procox® is approved in 27 EU countries and the first launches are planned for quarter 3,

About Veraflox®
Veraflox® has proven outstanding efficacy across a range of infections in both cats and
dogs. Veraflox® is safe and well tolerated at the recommended therapeutic dose. In field
studies of over 700 dogs and cats, all adverse events with Veraflox® treatment were mild
and transient and comparable to the control group. Extensive ocular safety testing has
demonstrated that Veraflox® has no adverse effects on feline retinas, even at ten times
the recommend therapeutic dose. Veraflox® is palatable with simple once daily
formulations – flavoured tablets for dogs and cats and a convenient oral suspension for
cats – helping facilitate compliance whilst giving veterinarians optimal and flexible control
over infections. Unlike long-acting injectable antibiotics, veterinarians are able to fully
control treatment duration with Veraflox® as it is administered daily.

About Procox®
Procox® is the first parasiticide of its kind for the combination treatment of roundworm and
coccidia gastrointestinal parasitic infections in dogs. It treats infections with adult,
immature adult and larval stages of Toxocara canis and adult stages of Uncinaria
stenocephala and Ancylostoma caninum. In addition Procox® is effective against the
replication of coccidia and also against the shedding of oocysts, thereby reducing the

                                           - 2/3 -
spread of infection. Procox® is available in an easy and convenient oral suspension. One
administration is generally sufficient though it can be given every two weeks, on up to five
occasions if required.

About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health
care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with
annual sales of EUR 16.913 billion (2010), is one of the world’s leading, innovative
companies in the healthcare and medical products industry and is based in Leverkusen,
Germany. The company combines the global activities of the Animal Health, Consumer
Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover
and manufacture products that will improve human and animal health worldwide. Bayer
HealthCare has a global workforce of 55,700 employees (Dec 31, 2010) and is
represented in more than 100 countries. Find more information at

With a turnover of EUR 1.120 million (2010) Bayer HealthCare’s Animal Health Division is
one of the world’s leading manufacturers of veterinary drugs. The division manufactures
and markets more than 100 different veterinary drugs and care products for livestock and
companion animals.

Kathrin Statz, Tel. +49 2173 38-4019

Find more information at
kst         (2011-0208e)

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer
Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to
material differences between the actual future results, financial situation, development or performance of the company
and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on
the Bayer website at The company assumes no liability whatsoever to update these forward-looking
statements or to conform them to future events or developments.

                                                      - 3/3 -

To top